Veracyte share price today

(VCYT)

Veracyte share price is $40.89 & ₹3,474.67 as on 21 Dec 2024, 2.30 'hrs' IST

$40.89

▲

1.82

(4.66%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Veracyte share price in Dollar and Rupees. Guide to invest in Veracyte from India. Also see the sentimental analysis on Indian investors investing in Veracyte. Get details on the Indian mutual funds that are investing in Veracyte. Get Analyst recommendations and forecasts along with all the Veracyte's financials.

Veracyte share price movements

Today's Low: $38.44
Today's High: $41.35
$40.89
5.99%
Downside
Day's Volatility :7.04%
Upside
1.11%
52 Weeks Low: $18.61
52 Weeks High: $46.00
$40.89
54.49%
Downside
52 Weeks Volatility :59.54%
Upside
11.11%

Veracyte Returns

Period	Veracyte, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	19.35%	-11.1%	0.0%
6 Months	78.25%	-6.0%	0.0%
1 Year	43.27%	2.7%	0.0%
3 Years	0.99%	0.6%	-19.7%

Veracyte Key Statistics

in dollars & INR

Previous Close	$39.07
Open	$38.53
Today's High	$41.35
Today's Low	$38.44
Market Capitalization	$3.2B
Today's Volume	$1.7M
52 Week High	$46.0
52 Week Low	$18.61
Revenue TTM	$425.3M
EBITDA	$44.0M
Earnings Per Share (EPS)	$-0.13
Profit Margin	-2.18%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-0.83%

How to invest in Veracyte from India?

It is very easy for Indian residents to invest directly in Veracyte from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Veracyte stock in both Indian Rupees (INR) and US Dollars (USD). Search for Veracyte or VCYT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Veracyte or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Veracyte shares which would translate to 0.021 fractional shares of Veracyte as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Veracyte, in just a few clicks!

Returns in Veracyte for Indian investors in Rupees

Investment Value

₹1,00,000

Veracyte investment value today

Current value as on today

₹1,45,469

Returns

₹45,469

(+45.47%)

Returns from Veracyte Stock

₹43,273 (+43.27%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Veracyte

90%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Veracyte on INDmoney from India has grown in the last 30 days as on Dec 22, 2024. 90% more investors are searching Veracyte in the last 30 days versus the previous period.

Global Institutional Holdings in Veracyte

BlackRock Inc
10.06%
Vanguard Group Inc
10.00%
Artisan Partners Limited Partnership
6.48%
ARK Investment Management LLC
6.35%
Wellington Management Company LLP
5.46%
Dimensional Fund Advisors, Inc.
3.91%

Analyst Recommendation on Veracyte

Buy

73%Buy

20%Hold

6%Sell

Based on 15 Wall street analysts offering stock ratings for Veracyte(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Veracyte

What analysts predicted

Upside of 5.7%

Current:

$40.89

Target:

$43.22

Insights on Veracyte

Price Movement
In the last 6 months, VCYT stock has moved up by 81.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 96.84M → 115.86M (in $), with an average increase of 8.3% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -29.61M → 15.15M (in $), with an average increase of 404.3% per quarter

Veracyte Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$92.0M	↑ 27.87%
Net Income	$-23.0M	↓ 25.82%
Net Profit Margin	-25.0%	↑ 18.09%

	FY19	Y/Y Change
Revenue	$120.4M	↑ 30.82%
Net Income	$-16.5M	↓ 28.34%
Net Profit Margin	-13.69%	↑ 11.31%

	FY20	Y/Y Change
Revenue	$117.5M	↓ 2.4%
Net Income	$-35.8M	↑ 117.51%
Net Profit Margin	-30.51%	↓ 16.82%

	FY21	Y/Y Change
Revenue	$219.5M	↑ 86.85%
Net Income	$-75.6M	↑ 110.79%
Net Profit Margin	-34.42%	↓ 3.91%

	FY22	Y/Y Change
Revenue	$296.5M	↑ 35.09%
Net Income	$-36.6M	↓ 51.62%
Net Profit Margin	-12.33%	↑ 22.09%

	FY23	Y/Y Change
Revenue	$361.1M	↑ 21.76%
Net Income	$-74.4M	↑ 103.51%
Net Profit Margin	-20.61%	↓ 8.28%

	Q2 FY23	Q/Q Change
Revenue	$90.3M	↑ 9.58%
Net Income	$-8.4M	↑ 47.82%
Net Profit Margin	-9.3%	↓ 2.4%

	Q3 FY23	Q/Q Change
Revenue	$90.1M	↓ 0.24%
Net Income	$-29.6M	↑ 252.51%
Net Profit Margin	-32.87%	↓ 23.57%

	Q4 FY23	Q/Q Change
Revenue	$98.2M	↑ 8.98%
Net Income	$-28.3M	↓ 4.47%
Net Profit Margin	-28.81%	↑ 4.06%

	Q1 FY24	Q/Q Change
Revenue	$96.8M	↓ 1.38%
Net Income	$-1.9M	↓ 93.41%
Net Profit Margin	-1.92%	↑ 26.89%

	Q2 FY24	Q/Q Change
Revenue	$114.4M	↑ 18.16%
Net Income	$5.7M	↓ 407.62%
Net Profit Margin	5.01%	↑ 6.93%

	Q3 FY24	Q/Q Change
Revenue	$115.9M	↑ 1.25%
Net Income	$15.2M	↑ 164.3%
Net Profit Margin	13.08%	↑ 8.07%

	FY18	Y/Y Change
Profit	$58.9M	↑ 34.67%

	FY19	Y/Y Change
Profit	$83.8M	↑ 42.28%

	FY20	Y/Y Change
Profit	$76.0M	↓ 9.32%

	FY21	Y/Y Change
Profit	$145.1M	↑ 90.87%

	FY22	Y/Y Change
Profit	$195.0M	↑ 34.35%

	FY23	Y/Y Change
Profit	$248.1M	↑ 27.29%

	Q2 FY23	Q/Q Change
Profit	$60.6M	↑ 7.9%

	Q3 FY23	Q/Q Change
Profit	$62.5M	↑ 3.07%

	Q4 FY23	Q/Q Change
Profit	$63.2M	↑ 1.05%

	Q1 FY24	Q/Q Change
Profit	$60.5M	↓ 4.16%

	Q2 FY24	Q/Q Change
Profit	$75.8M	↑ 25.21%

	Q3 FY24	Q/Q Change
Profit	$79.0M	↑ 4.26%

	FY18	Y/Y Change
Operating Cash Flow	$-13.5M	↓ 43.46%
Investing Cash Flow	$-1.9M	↑ 56.82%
Financing Cash Flow	$59.5M	↓ 27393.12%

	FY19	Y/Y Change
Operating Cash Flow	$-3.2M	↓ 76.1%
Investing Cash Flow	$-42.7M	↑ 2180.31%
Financing Cash Flow	$127.3M	↑ 113.93%

	FY20	Y/Y Change
Operating Cash Flow	$-9.7M	↑ 200.46%
Investing Cash Flow	$-3.8M	↓ 91.02%
Financing Cash Flow	$203.6M	↑ 59.95%

	FY21	Y/Y Change
Operating Cash Flow	$-31.6M	↑ 225.62%
Investing Cash Flow	$-739.2M	↑ 19165.21%
Financing Cash Flow	$596.3M	↑ 192.9%

	FY22	Y/Y Change
Operating Cash Flow	$7.5M	↓ 123.83%
Investing Cash Flow	$-29.4M	↓ 96.02%
Financing Cash Flow	$3.5M	↓ 99.41%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$16.7M	↓ 867.54%
Investing Cash Flow	$-3.7M	↓ 115.24%
Financing Cash Flow	$397.0K	↓ 76.44%

Veracyte Technicals Summary

Sell

Neutral

Buy

Veracyte is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Veracyte Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Veracyte, Inc.	5.01%	78.25%	43.27%	0.99%	38.14%
Idexx Laboratories, Inc.	-1.19%	-16.12%	-25.85%	-36.09%	56.6%
Agilent Technologies Inc.	0.5%	-0.42%	-3.79%	-14.76%	57.69%
Thermo Fisher Scientific, Inc.	2.1%	-7.4%	-1.07%	-19.46%	60.5%
Danaher Corp.	-3.09%	-10.99%	-1.23%	-28.75%	49.05%
Iqvia Holdings Inc.	-2.25%	-7.86%	-14.61%	-29.04%	27.52%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Veracyte, Inc.	NA	NA	0.0	1.01	-0.01	0.01	NA	15.18
Idexx Laboratories, Inc.	39.52	39.52	4.31	10.73	0.59	0.23	NA	19.72
Agilent Technologies Inc.	30.02	30.02	2.26	5.24	0.25	0.08	0.01	20.53
Thermo Fisher Scientific, Inc.	32.35	32.35	1.97	21.7	0.13	0.05	0.0	128.08
Danaher Corp.	42.75	42.75	3.02	7.5	0.08	0.04	0.0	71.03
Iqvia Holdings Inc.	25.19	25.19	1.01	11.11	0.22	0.05	NA	38.37

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Veracyte, Inc.	Buy	$3.2B	38.14%	NA	-2.18%
Idexx Laboratories, Inc.	Buy	$33.5B	56.6%	39.52	22.53%
Agilent Technologies Inc.	Buy	$38.4B	57.69%	30.02	21.75%
Thermo Fisher Scientific, Inc.	Buy	$197.6B	60.5%	32.35	14.48%
Danaher Corp.	Buy	$163.3B	49.05%	42.75	16.39%
Iqvia Holdings Inc.	Buy	$35.8B	27.52%	25.19	9.17%

Veracyte Dividend announcements

Veracyte Earnings
Veracyte’s price-to-earnings ratio stands at None
Read More

About Veracyte

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .

Organization	Veracyte
Employees	815
CEO	Mr. Marc A. Stapley
Industry	Health Technology

Management People of Veracyte

Name	Title
Mr. Marc A. Stapley	CEO & Director
Ms. Rebecca Chambers	Executive VP & CFO
Dr. Phillip G. Febbo M.D.	Chief Scientific & Medical Officer
Ms. Annie McGuire	Executive VP, General Counsel & Chief People Officer
Dr. John Leite Ph.D.	Chief Commercial Officer
Dr. Keith Gligorich Ph.D.	Senior Vice President of Global Operations
Mr. Jonathan Wygant	VP & Chief Accounting Officer
Mr. Steven French	Senior VP & Chief Information Officer
Ms. Karen Possemato	Senior Vice President of Corporate Marketing, Communications & Commercial Operations
Mr. Robert Brainin	Executive VP & Chief Business Officer

Important FAQs about investing in Veracyte from India :

What is Veracyte share price today?

Veracyte share price today stands at $40.89, Open: $38.53 ; Previous Close: $39.07 ; High: $41.35 ; Low: $38.44 ; 52 Week High: $46.00 ; 52 Week Low: $18.61. The stock opens at $38.53, after a previous close of $39.07. The stock reached a daily high of $41.35 and a low of $38.44, with a 52-week high of $46.00 and a 52-week low of $18.61.

Can Indians buy Veracyte shares?

Yes, Indians can invest in the Veracyte (VCYT) from India.

With INDmoney, you can buy Veracyte at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Veracyte at zero transaction cost.

How can I buy Veracyte shares from India?

It is very easy to buy Veracyte from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Veracyte be purchased?

Yes, you can buy fractional shares of Veracyte with INDmoney app.

What are the documents required to start investing in Veracyte stocks?

To start investing in Veracyte, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.